Changes in Hong Kong stocks | Jietai Technology-P (07666) rose more than 11% in the intraday period and joined hands with Zhaoyan Pharmaceutical to build an innovative mRNA drug development and industrial manufacturing platform

The Zhitong Finance App learned that Jitai Technology-P (07666) rose more than 11% during the intraday period. As of press release, it had risen 10.67% to HK$15.12, with a turnover of HK$83.3917 million.

According to news, recently, according to Jietai Science and Technology's WeChat account, the company and Zhaobian Biotech formally signed a joint venture agreement to jointly establish a joint venture company, Zhaotai Intelligent Pharmaceutical, to jointly build a platform for innovative research and development and industrial manufacturing of mRNA drugs. At present, the first joint project between the two parties has been launched. According to the agreement, Jietai Technology will provide design and delivery capabilities upstream, and NanoForge has achieved targeted delivery to 8 key organs and tissues in the human body.

Ms. Feng Yuxia, Chairman of Zhaoyan Pharmaceutical, said, “The joint establishment of a joint venture between Zhaoyan Biotech and Jetai Life is an important practice of complementary advantages and collaborative development between the two parties. Jietai Life has outstanding innovative capabilities in the field of AI-driven mRNA sequence design and nano-delivery, while Zhaobian Biotech has accumulated solid experience in process development and industrialization in the field of macromolecular drug CDMO. We hope that through this cooperation, the R&D and manufacturing capabilities of both parties will be effectively integrated to jointly provide a one-stop service from design to production for the development of new mRNA drugs.”